Can Ascletis ASC37 become a once-monthly triple agonist for obesity?
Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.
Pharma & Biotech
Pharma & Biotech
Retatrutide TRIUMPH-3 trial advances Eli Lilly’s 2027 FDA filing plan
Eli Lilly’s retatrutide delivered up to 22.6% weight loss in two Phase 3 trials as a 2027 FDA filing moves closer.
Pharma & Biotech
Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Pharma & Biotech
Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?
Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.
Pharma & Biotech
Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide
Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site
Pharma & Biotech
Why Eli Lilly’s triple agonist may become the first obesity drug with dual indications
Eli Lilly and Company has announced successful topline results from its Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a triple hormone receptor agonist, in adults with obesity and knee osteoarthritis. The once-weekly investigational therapy delivered significant dual benefits: an average weight loss of 28.7 percent and a 75.8 percent reduction in joint pain, measured by